Home›Trial›NCT07030712
🔬NCT07030712Phase 1RECRUITING

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

Study Summary

MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.

Conditions
Metastatic Neoplasm
Interventions / Drugs
MK-8294MK-8294MK-8294MK-8294MK-8294MK-8294MK-8294MK-8294CD8 PET Tracer
View on ClinicalTrials.gov ↗
Sponsor
MRK
Merck & Co
Oncology/Vaccines
F34/100
Study Details
Enrollment67 participants
Primary Completion—
Lead SponsorMerck Sharp & Dohme LLC
Data Retrieved2026-04-11 02:55:36.205781+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.